Clinical Trials
6 trialsNCT04305054 2026-05-28
KEYMAKER-U02
Merck Sharp & Dohme LLC
Phase 1/2 Completed
NCT03530397 2026-05-19
A Study to Evaluate MEDI5752 in Subjects With Advanced Solid Tumors
MedImmune LLC
Phase 1 Active not recruiting
NCT03058289 2025-02-27
IT-01
Intensity Therapeutics, Inc.
Phase 1/2 Completed
NCT05824975 2024-11-25
A Study to Evaluate the Safety and Therapeutic Activity of GI-102 As a Single Agent and in Combination with Conventional Anti-cancer Drugs, Pembrolizumab or Trastuzumab Deruxtecan(T-DXd) in Patients with Advanced Solid Tumors (KEYNOTE-G08)
GI Innovation, Inc.
Phase 1/2 Recruiting
NCT03302234 2023-09-26
KEYNOTE-598
Merck Sharp & Dohme LLC
Phase 3 Completed
NCT03849469 2023-03-30
DUET-4
Xencor, Inc.
Phase 1 Completed